Bli medlem
Bli medlem

Du är här

2022-09-22

Targinta appoints Peter Ekolind as acting CEO

Targinta's board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén's resignation as CEO.

Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development companies. Previous experiences include various positions such as CEO, business area manager and COO. Peter has good knowledge in product development, sales, marketing, capitalization, preclinical development and GMP manufacturing. For the past two years, Peter has worked as COO in Xintela.

"It feels natural to me to lead Targinta until there is a long-term solution in place. I know the company well and there is a competent team working to develop the company and its products," says Peter Ekolind.

"With his broad experience and knowledge of the company, Peter Ekolind will have good conditions to push the company further forward in the development work," says Greg Batcheller, chairman of the board of Targinta.

For further information please contact:
Greg Batcheller, Chairman Targinta AB
Email: greg@xintela.se
Phone: +46 46 275 65 00

About Targinta


Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin α10β1. The pipeline includes TARG10, a function-blocking intergrin α10-antibody that is being developed to prevent metastasis, and TARG9, an intergrin α10-ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit www.targinta.se.

About Xintela


Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments


Targinta appoints Peter Ekolind as acting CEO

Författare MFN